B of A Securities Maintains Buy on Vaxcyte, Lowers Price Target to $130
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
B of A Securities analyst Jason Gerberry maintains Vaxcyte (NASDAQ:PCVX) with a Buy and lowers the price target from $133 to $130.
B of A Securities analyst Jason Gerberry maintains Vaxcyte (NASDAQ:PCVX) with a Buy and lowers the price target from $133 to $130.